View in EDS

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

Saved in:
Bibliographic Details
Title: Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
Authors: Blaye C; Department of Medical Oncology, Institut Bergonié, ImmunoConcEpT, CNRS 5164, Bordeaux, France., Bidard FC; Department of Medical Oncology, Institut Curie Paris et Saint Cloud, INSERM CIC1428, Université de Versailles-Saint-Quentin, Université Paris-Saclay, Saint Cloud, France., Hue L; Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France., Howarth K; SAGA Diagnostics, Lund, Sweden., Pierga JY; Department of Medical Oncology, Institut Curie - Paris, Université Paris Cité, Paris, France., Dalenc F; Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-Oncopole, Université de Toulouse, Toulouse, France., Jacot W; Department of Medical Oncology, Institut du cancer de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France., Djerroudi L; Department of Biopathology, Institut Curie - Paris, Paris, France., Potonnier W; Department of Biopathology, Institut Curie - Saint Cloud, France., Dumas V; Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France., Lalet C; Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France., Maréchal M; Department of Biopathology, Institut Bergonié, Bordeaux, France., Pulido M; Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC1401, Bordeaux, France., Brunet M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Salabert L; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Venat L; Department of Medical Oncology, CHU Limoges, Limoges, France., Maran-Gonzalez A; Department of Pathology, Institut du cancer de Montpellier, Montpellier, France., Saal LH; Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden; Skåne University Hospital Comprehensive Cancer Centre, Lund, Sweden., Franchet C; Department of Biopathology, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France., Birkeälv S; SAGA Diagnostics, Lund, Sweden., MacGrogan G; Department of Biopathology, Institut Bergonié, INSERM U1312 BRIC, Bordeaux, France., Bonnefoi H; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Université de Bordeaux UFR Collège Sciences de la Santé, Bordeaux, France. Electronic address: h.bonnefoi@bordeaux.unicancer.fr.
Source: ESMO open [ESMO Open] 2026 Jun; Vol. 11 (6), pp. 107766. Date of Electronic Publication: 2026 Jun 04.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2059-7029
DOI:10.1016/j.esmoop.2026.107766